[{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entos Pharmaceuticals Is Developing a DNA Vaccine Against COVID-19 Using Its Fusogenix Nanomedicine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Fusogenix DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"EpiVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Epivax and Entos Pharmaceuticals to develop DNA-based vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Fusogenix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Entos Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"GE Healthcare Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytiva and Entos Pharmaceuticals work together to accelerate development of COVID19 vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Covigenix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Entos Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Canadian Institutes of Health Research (CIHR)","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Entos Pharmaceuticals Announces Selection of Lead DNA Vaccine Candidates for COVID-19 and a $4.2M Award","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Fusogenix DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Canadian Institutes of Health Research (CIHR)","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entos Pharmaceuticals Awarded Funding to Conduct Phase I Clinical Trial of COVID-19 DNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Covigenix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Entos Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ NRC IRAP","highestDevelopmentStatusID":"6","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Entos and BioMarin Enter into Agreement for Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Fusogenix-formulated Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Entos Pharmaceuticals \/ BioMarin","highestDevelopmentStatusID":"1","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"$50.0 million","newsHeadline":"Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Nucleic acid-based Therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Alberta Cancer Foundation","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Alberta Cancer Foundation Announces Initial Investment of its Novel Philanthropic Breakthrough Fund to Support Early-Stage Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Alberta Cancer Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entos Gets Approval to Begin Clinical Trial for COVID-19 Vaccine Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Covigenix VAX-002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Entos Phar.."}]

Find Clinical Drug Pipeline Developments & Deals by Entos Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Entos investigational product Covigenix VAX-002 is a plasmid DNA vaccine, which is being evaluated in the Phase 1/2 clinical trial studies to treat COVID-19.

                          Product Name : Covigenix VAX-002

                          Product Type : Vaccine

                          Upfront Cash : Not Applicable

                          June 10, 2024

                          Lead Product(s) : Covigenix VAX-002

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Alberta Cancer Foundation

                          Deal Size : $0.1 million

                          Deal Type : Funding

                          Details : The funding is intended to aid Entos in advancing a personalized immunotherapy strategy for treating cancer patients with advanced disease. This approach involves utilizing DNA vaccines tailored to target...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 23, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Alberta Cancer Foundation

                          Deal Size : $0.1 million

                          Deal Type : Funding

                          blank

                          03

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Nucleic acid-based Therapies

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Eli Lilly

                          Deal Size : $450.0 million

                          Deal Type : Collaboration

                          Details : Under the terms of the research and collaboration agreement, Lilly and Entos have agreed to multiple programs focused on the development of proteo-lipid vehicles (PLV) for delivery of therapeutic cargo su...

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : $50.0 million

                          January 06, 2022

                          Lead Product(s) : Nucleic acid-based Therapies

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Eli Lilly

                          Deal Size : $450.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Under the terms of the agreement, Entos will use its Fusogenix nucleic acid delivery system to specially formulate BioMarin products directed at multiple undisclosed genetic disease indications.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 15, 2021

                          Lead Product(s) : Fusogenix-formulated Gene Therapy

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Partner/Sponsor/Collaborator : BioMarin Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Entos developed a Fusogenix DNA vaccine called Covigenix, that in preclinical studies, induces a strong neutralizing antibody response plus a potent and balanced T cell response against SARS-CoV-2, the vi...

                          Product Name : Covigenix

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          October 23, 2020

                          Lead Product(s) : Covigenix

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Partner/Sponsor/Collaborator : NRC IRAP

                          Deal Size : $5.0 million

                          Deal Type : Funding

                          blank

                          06

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Fusogenix DNA vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Canadian Institutes of Health Research (CIHR)

                          Deal Size : $4.2 million

                          Deal Type : Funding

                          Details : Company announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine (Covigenix) from its prototyping program launched at the onset of the global COVID-19 pandemic.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 25, 2020

                          Lead Product(s) : Fusogenix DNA vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Canadian Institutes of Health Research (CIHR)

                          Deal Size : $4.2 million

                          Deal Type : Funding

                          blank

                          07

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Cytiva’s Fast Trak process development team will use their expertise to develop a scalable downstream protein purification method that will enable GMP-production of the Fusogenix protein component that ...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 01, 2020

                          Lead Product(s) : Covigenix

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : GE Healthcare Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : This partnership will combine the Entos Fusogenix DNA delivery technology with optimized COVID-19 epitopes from EpiVax to generate a highly effective immune response against the novel coronavirus.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 28, 2020

                          Lead Product(s) : Fusogenix

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : EpiVax

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Fusogenix DNA vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : The vaccine payload will be plasmid DNA encoding multiple antigens from key SARS-CoV-2 proteins to promote maximum protection.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Not Applicable

                          March 18, 2020

                          Lead Product(s) : Fusogenix DNA vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank